Asensus Surgical

Asensus Surgical CapEx/D&A

Delisted

The CapEx to Depreciation Ratio of Asensus Surgical (ASXC) as of Oct 22, 2026 is 1.24. In the previous year, CapEx to Depreciation Ratio was 0.17 — a change of 646.53% (higher).

CapEx/D&A

1.24

YoY

646.53%

Last updated:

CapEx to Depreciation Ratio of Asensus Surgical is 2023 1.24 . CapEx to Depreciation Ratio of Asensus Surgical was 2022 0.17 . It decreases by 646.53% higher compared to the previous year.

The Asensus Surgical CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2016
0.20 USD
Jan 1, 2017
0.25 USD
Jan 1, 2018
0.07 USD
Jan 1, 2019
0.04 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.12 USD
Jan 1, 2022
0.17 USD
Jan 1, 2023
1.24 USD
The Asensus Surgical CapEx/D&A history
YEARCapEx/D&AYoY
1.24+646.53%
0.17+36.42%
0.12+43,676.00%
0.00-99.35%
0.04-40.11%
0.07-72.04%
0.25+29.72%
0.20-65.35%
0.56-87.04%
4.35—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Asensus Surgical Stock analysis

What does Asensus Surgical do? Asensus Surgical Inc is a medical technology company based in Research Triangle Park, North Carolina, USA. It was founded in 1995 by Joe Mussallem, who still serves as President and CEO today. Formerly known as "TransEnterix," the company changed its name to Asensus Surgical Inc in 2021 to reflect its commitment to advanced, data-driven surgery. Asensus Surgical Inc aims to revolutionize the way surgical procedures are performed by utilizing robotic technology and offering a wide range of products and services. The company's business model is based on transferring skills typically held by surgeons to robots, with a focus on precision in surgeries. Through the use of machine learning and computer vision, Asensus Surgical Inc allows surgeons to monitor their own movements in real-time on robotic arms in the operating room, leading to significantly more precise work. The company's main division is the Senhance® Surgical System platform. The system consists of three components: the artificial intelligence technology of the Intelligent Surgical Units (ISU), touchscreen consoles, and a further sterilization cabinet. During surgical procedures, the Intelligent Surgical Units process real-time data, enabling improved decision-making during the operation. The touchscreen consoles serve as the user interface, allowing surgeons to monitor and control the operation in real-time on a screen. The sterilization cabinet ensures that the system is sterilized between procedures. In addition to the Senhance® Surgical System platform, Asensus Surgical Inc also offers other innovative products such as disposable instruments. This includes "3-mm instruments," special miniature instruments that can be used through very small incisions in the patient's body. These minimize scarring and enable faster recovery. Another product offered by Asensus Surgical Inc is the AI Camera Assistant, which is based on artificial intelligence (AI). This is a computer software that supports surgeons by analyzing real-time images and enabling monitoring and analysis during the procedure. Combined with the Senhance® Surgical System, the AI Camera Assistant allows for more precise and safer work. Asensus Surgical Inc has achieved several significant milestones in its history. One of these milestones is the FDA approval of the Senhance® Surgical System platform in 2017. Furthermore, in 2020, the company entered into an agreement with Johnson & Johnson to advance the marketing of products. Overall, Asensus Surgical Inc is an emerging company in the highly innovative field of robotics in surgery. With its advanced products and focus on precise, safe, and straightforward surgery, the company will continue to play an important role in the healthcare industry, saving and improving lives. Asensus Surgical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Asensus Surgical stock

CapEx to Depreciation Ratio of Asensus Surgical is 1.24 in 2023.

CapEx to Depreciation Ratio of Asensus Surgical changed from 0.17 to 1.24, representing a 646.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Asensus Surgical since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Asensus Surgical with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Asensus Surgical

All Key Metrics — Asensus Surgical